Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea

Seoul National University Hospital100 enrolled

Overview

The aim of this study is to assess the prognosis of paroxysmal kinesigenic choreoathetosis (PKC) in Korean.

PKC is a hyperkinetic movement disorder including dystonia, chorea, athetosis, or ballism, which are characteristically triggered by a sudden movement from rest. The prevalence of this disorder is estimated to be 1 in 150,000 population. Males are more commonly affected than females, and the age of onset is typically in childhood or adolescence. PKC is mainly a familial disorder with autosomal dominant inheritance and incomplete penetrance, but it can occur sporadically. The PRRT2 (proline-rich transmembrane protein 2) gene is believed to be the major causative gene. The prognosis of PKC is usually favorable. The severity and frequency of the attacks are reduced by anticonvulsant medication such as carbamazepine, and the number of the attacks decreases at the age of 20-30 years. However, there has been little study of long-term prognosis of PKC, and no study has been conducted in Korean population.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Paroxysmal Kinesigenic Choreoathetosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female PKC patients who were18 years of age and older * Subjects were diagnosed as paroxysmal kinesigenic choreoathetosis (PKC) * Subjects were enrolled voluntarily and understood the contents of this trial Exclusion Criteria: * Existence of lesions on the brain * Existence of neurological deficit that suspected lesions on the brain * Existence of epileptiform discharges on electroencephalogram * Subjects with secondary PKC which was caused by other disorder or illness * Existence of illness or problems which made difficult to be enrolled to this trial judged by clinicians

Locations (1)

Seoul National University Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Changes in clinical characteristics of PKC relative to the baseline.

Improvement or worsening of the attacks relative to the baseline state assessed by a questionnaire, categorized as following; 1, full remission (absence of the attacks); 2, improvement (more than 50% decreased mean frequency of the attacks); 3, worsening (increased frequency of the attacks).

Time frame: up to 10 years

Changes in clinical characteristics of PKC over the last year.

Improvement or worsening of the attacks over the last year assessed by a questionnaire, categorized as following; 1, full remission (absence of the attacks); 2, improvement (more than 50% decreased mean frequency of the attacks); 3, worsening (increased frequency of the attacks).

Time frame: up to 10 years

Changes in medication history of PKC over the last year.

Continuation or discontinuation of the medication for relief of the attacks assessed by a questionnaire, categorized as following; 1, continuation of medication; 2, discontinuation of medication.

Time frame: up to 10 years

Central Contacts

Han-joon Kim, MD, Ph.D

CONTACT

+82-2-2072-1219 movement@snu.ac.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.